The ACCORD, ADVANCE and VA Diabetes Trials seem to indicate that there is no real benefit of intensive glycemic control on cardiovascular events in patients with type 2 diabetes. Join host Dr. Steven Edelman and his guest, executive director of the International Diabetes Center at Park Nicollet, Dr. Richard Bergenstal, as they discuss the implications on clinical care and benefits of glycemic control.
Implications of the ACCORD, ADVANCE and VA Diabetes Trials

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The ACCORD, ADVANCE and VA Diabetes Trials seem to indicate that there is no real benefit of intensive glycemic control on cardiovascular events in patients with type 2 diabetes. Join host Dr. Steven Edelman and his guest, executive director of the International Diabetes Center at Park Nicollet, Dr. Richard Bergenstal, as they discuss the implications on clinical care and benefits of glycemic control.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Crossroads in PBC Care: When First-Line Therapy Falls Short
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
HF Management for Patients with Comorbid Conditions
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
CETP inhibition: Lessons from two decades of clinical trials
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Diagnostic Advances in gMG: Effective Tools and Techniques
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?